Close Menu

NEW YORK – Genetic Signatures said Wednesday it has received the CE mark for its severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) detection kit, enabling the kit to be marketed in the European Union and other countries that recognize the designation.

Using samples collected from nose or throat swabs, the kit can run on Genetic Signatures' highest throughput instrument, the GS-1000, which can process about 1,500 samples in a 24-hour period, in a fully staffed laboratory and in batches of 188 samples per run, the firm said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to CNBC, Pfizer has announced that its SARS-CoV-2 vaccine data won't be ready this week.

A number of United Nations agencies push for scientific findings to be made accessible through open science.

Paris-Saclay University garners international regard following a decade-long effort to establish the new research university, Nature News reports.

In Nucleic Acids Research this week: database to house IndiGen sequencing data, database of SARS-CoV-2 docking scores, and more.